与子宫肌瘤相关月经过多女性中艾拉戈利联合反向添加治疗的应答预测因素
该分析汇总了两项多中心、双盲、随机、安慰剂对照的3期研究(Elaris Uterine Fibroids 1和2)数据,评估艾拉戈利(300 mg每日两次)联合反向添加治疗(1 mg雌二醇/0.5 mg醋酸炔诺酮每日一次)治疗6个月在各亚组中减少子宫肌瘤相关月经过多的疗效与安全性。结果显示各亚组中艾拉戈利联合反向添加治疗组的应答比例、月经过血量变化、闭经率、症状严重程度改善及健康相关生活质量评分均临床意义显著优于安慰剂组,且不良事件与总体人群一致。
要点
- 各亚组中艾拉戈利联合反向添加治疗的应答率均临床意义显著高于安慰剂。
- 总体主要终点应答率为72.2% vs 9.3%,闭经率为50.4% vs 4.5%。
- 疗效不受年龄、体质指数、种族、民族、基线失血量、肌瘤位置及体积影响。
核心结论
- 艾拉戈利联合激素反向添加治疗可有效减少子宫肌瘤相关月经过多,且疗效不依赖于年龄、体质指数、种族、民族、基线月经过血量、肌瘤位置及子宫和主要肌瘤体积。
研究设计与样本
- 汇总Elaris Uterine Fibroid-1和Uterine Fibroid-2两项多中心、双盲、随机、安慰剂对照的3期研究数据。
- 纳入18-51岁、经碱性血红素法证实月经过多(>80 mL/周期)且超声确诊子宫肌瘤的绝经前女性。
- 分析亚组包括年龄、体质指数、种族、民族、基线月经过血量、肌瘤位置及子宫和主要肌瘤体积。
主要发现
- 总体汇总人群平均年龄42.4岁(标准差5.4),平均体质指数33.6 kg/m2(标准差7.3),67.6%为黑人或非裔美国人。
- 主要终点应答率:艾拉戈利联合反向添加治疗组72.2% vs 安慰剂组9.3%。
- 月经过血量平均变化:艾拉戈利联合反向添加治疗组-172.5 mL vs 安慰剂组-0.8 mL。
- 闭经率:艾拉戈利联合反向添加治疗组50.4% vs 安慰剂组4.5%。
- 症状严重程度变化:艾拉戈利联合反向添加治疗组-37.1 vs 安慰剂组-9.2;健康相关生活质量评分变化:39.9 vs 8.9。
关键数值与推荐
- 主要终点为最终月月经过血量<80 mL且较基线减少≥50%的女性比例。
- 艾拉戈利剂量为300 mg每日两次,反向添加治疗为1 mg雌二醇/0.5 mg醋酸炔诺酮每日一次。
- 治疗持续6个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uterine fibroids are one of the most common neoplasms found among women globally, with a prevalence of approximately 11 million women in the United States alone. The morbidity of this common disease is significant because it is the leading cause of hysterectomy and causes significant functional impairment for women of reproductive age. Factors including age, body mass index, race, ethnicity, menstrual blood loss, fibroid location, and uterine and fibroid volume influence the incidence of fibroids and severity of symptoms. Elagolix is an oral gonadotropin-releasing hormone receptor antagonist that competitively inhibits pituitary gonadotropin-releasing hormone receptor activity and suppresses the release of gonadotropins from the pituitary gland, resulting in dose-dependent suppression of ovarian sex hormones, follicular growth, and ovulation. In Elaris Uterine Fibroids 1 and Uterine Fibroids 2, 2 replicate multicenter, double-blind, randomized, placebo-controlled, phase 3 studies, treatment of premenopausal women with elagolix with hormonal add-back therapy demonstrated reduction in heavy menstrual bleeding associated with uterine fibroids. OBJECTIVE: This analysis aimed to evaluate the safety and efficacy of elagolix (300 mg twice a day) with add-back therapy (1 mg estradiol/0.5 mg norethindrone acetate once a day) in reducing heavy menstrual bleeding associated with uterine fibroids in various subgroups of women over 6 months of treatment. STUDY DESIGN: Data were pooled from Elaris Uterine Fibroid-1 and Uterine Fibroid-2 studies, which evaluated premenopausal women (18-51 years) with heavy menstrual bleeding (>80 mL menstrual blood loss per cycle, alkaline hematin methodology) and ultrasound-confirmed uterine fibroid diagnosis. Subgroups analyzed included age, body mass index, race, ethnicity, baseline menstrual blood loss, fibroid location, and uterine and primary fibroid volume (largest fibroid identified by ultrasound). The primary endpoint was the proportion of women with <80 mL menstrual blood loss during the final month and ≥50% menstrual blood loss reduction from baseline to final month. Secondary and other efficacy endpoints included mean change in menstrual blood loss from baseline to final month, amenorrhea, symptom severity, and health-related quality of life. Adverse events and other safety endpoints were monitored. RESULTS: The overall pooled Elaris Uterine Fibroid-1 and Uterine Fibroid-2 population was typical of women with fibroids, with a mean age of 42.4 (standard deviation, 5.4) years and a mean body mass index of 33.6 (standard deviation, 7.3) kg/m2 and 67.6% of participants being black or African American women. A wide range of baseline uterine and fibroid volumes and menstrual blood loss were also represented in the overall pooled study population. In all subgroups, the proportion of responders to the primary endpoint, mean change in menstrual blood loss, amenorrhea, reduction in symptom severity, and improvement in health-related quality of life were clinically meaningfully greater for women who received elagolix with add-back therapy than those who received placebo and consistent with the overall pooled study population for the primary endpoint (72.2% vs 9.3%), mean change in menstrual blood loss (-172.5 mL vs -0.8 mL), amenorrhea (50.4% vs 4.5%), symptom severity (-37.1 vs -9.2), and health-related quality of life score (39.9 vs 8.9). Adverse events by subgroup were consistent with the overall pooled study population. CONCLUSION: Elagolix with hormonal add-back therapy was effective in reducing heavy menstrual bleeding associated with uterine fibroids independent of age, body mass index, race, ethnicity, baseline menstrual blood loss, fibroid location, and uterine and primary fibroid volume.
引用
- Al-Hendy A, Bradley L, Owens CD, et al. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids. Am J Obstet Gynecol. 2020. PMID: 32702363. doi:10.1016/j.ajog.2020.07.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。